Published in Pharma Law Weekly, March 21st, 2006
For the quarter ended December 31, 2005 Amarin reported a net loss of $5.2 million or 10 cents per American Depositary Share (ADS), compared with a net loss of $4.8 million or 13 cents per ADS in the quarter ended December 31, 2004. The net loss for the quarter primarily reflects Amarin's substantial investment in research and development and intellectual property offset by license fee revenue and a reduction in selling, general and administrative costs.
For the year ended December 31, 2005, Amarin reported a net loss of $18.7 million or...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Law Weekly